IKT

NASDAQ open

Inhibikase Therapeutics

1.35 USD
▲+0.04+3.46%
盘后 1.45 0.00%
2026-11-20
市值
$265.11M
市盈率
—
EPS
-0.41
股息率
—
52 周区间
1.22 – 2.61
成交量
110.02K
Beta
0.94
目标价
5.55
52W 低 1.2252W 高 2.61
价格走势

公司简介

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role...